Importantly, if low circulating levels of TGF-beta reflect low intratumoral TGF-beta and reduced immunosuppression, and higher PD-L1 levels in the plasma correlate positively with high PD-L1 tumor expression, we might speculate that metastatic PDAC patients with lower levels of circulating sTGF-beta and higher levels of sPD-L1 could be more receptive to immunotherapy with PD-L1 inhibitors. The gene discussed is CD274; the disease is neoplasm.